Fig. 1

A The tumor volume (Mean ± SD) in the treated and untreated control group (5 mice/group). Treated group consisted of mice (5 mice in each group) receiving daily intraperitoneal injections of naringenin (50 mg/kg/day) or CPT (20 mg/Kg/day) or their combination (naringenin + CPT) for 10 consecutive days. B Proliferation assay of splenocytes treated with naringenin alone (50 mg/kg/day) (Nar), CPT (20 mg/Kg/day), or naringenin (20 mg/kg/day) + CPT (20 mg/kg/day) (Nar + CPT) compared with the untreated control group (receiving DMSO as the solvent). C Levels of IFN-γ and IL-4 secreted from splenocytes stimulated by tumor antigen in animals treated with naringenin (Nar) alone or combined with CPT (Nar + CPT). D Percentage of intra-tumoral and splenic CD4⁺ CD25⁺ Foxp3⁺  T cells in animals treated with naringenin (Nar), either individually (50 mg/kg/day) or in combination with CPT (both with the concentration of 20 mg/kg/day). N = 5 in each group. * P < 0.05 and ** P < 0.01 represents significant differences in comparison with control values